Metabolic syndrome and renal disease

International Journal of Cardiology

Volumn 164, Issue 2, 2013, Pages 141-150

  Gluba, Anna ^a   Mikhailidis, Dimitri P ^b   Lip, Gregory Y H ^c   Hannam, Simon ^d   Rysz, Jacek ^a   Banach, MacIej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dyslipidemia; Kidney disease; Kidney stones; Metabolic syndrome; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; LACIDIPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; PRAVASTATIN; RIMONABANT; ROSUVASTATIN; ADIPONECTIN; ALDOSTERONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIDKINE; MINERALOCORTICOID RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; RENIN INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ARTERIOLOSCLEROSIS; BLOOD VESSEL INJURY; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE MARKER; DRUG FATALITY; DYSLIPIDEMIA; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY PERFUSION; KIDNEY TUBULE ATROPHY; KIDNEY TUBULE DISORDER; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; WEIGHT REDUCTION; ALBUMINURIA; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; B SCAN; CALCIUM EXCRETION; CALORIC RESTRICTION; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFICACY; ELEVATED BLOOD PRESSURE; END STAGE RENAL DISEASE; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; EXERCISE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DYSFUNCTION; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE CELL; LIFE EXPECTANCY; MENOPAUSE; MESANGIUM CELL; META ANALYSIS (TOPIC); MICROALBUMINURIA; NATRIURESIS; NEPHROLITHIASIS; NEPHROSIS; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPEN STUDY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PHYSICAL ACTIVITY; POST HOC ANALYSIS; PREVALENCE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEINURIA; PUBLIC HEALTH; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEVERE RENAL IMPAIRMENT; SIGNAL TRANSDUCTION; SMOKING; SMOKING CESSATION; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UNFOLDED PROTEIN RESPONSE; UPREGULATION; URINE PH; WEIGHT GAIN;

HUMANS; INSULIN RESISTANCE; KIDNEY DISEASES; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 84875219254     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.01.013     Document Type: Review

References (191)

1. I.H. Chang, J.H. Han, and S.C. Myung Association between metabolic syndrome and chronic kidney disease in the Korean population Nephrology 14 2009 321 326
2. Z. Rasic-Milutinovic, G. Perunicic, S. Pljesa, Z. Gluvic, M. Ilic, and E. Stokić Metabolic syndrome in HD patients: association with body composition, nutritional status, inflammation and serum iron Intern Med 46 2007 945 951
3. E. Hopps, D. Noto, G. Caimi, and M.R. Averna A novel component of the metabolic syndrome: the oxidative stress Nutr Metab Cardiovasc Dis 20 2010 72 77
4. G. Aldini, I. Dalle-Donne, R.M. Facino, A. Milzani, and M. Carini Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls Med Res Rev 27 2007 817 868
5. E.S. Ford, A.H. Mokdad, W.H. Giles, and D.W. Brown The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey Diabetes 52 2003 2346 2352
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III JAMA 285 2001 2486 2497
7. World Health Organization Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation 1999 World Health Organization Geneva
8. P. Zimmet, G. Alberti, and J. Shaw A new IDF worldwide definition of the metabolic syndrome: the rationale and the results Diabetes Voice 50 2005 31 33
9. K.G. Alberti, R.H. Eckel, and S.M. Grundy Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 120 2009 1640 1645
10. F. Locatelli, P. Pozzoni, and L. Del Vecchio Renal manifestations in the metabolic syndrome J Am Soc Nephrol 17 2006 S81 S85
11. B.E. Klein, R. Klein, and K.E. Lee Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam Diabetes Care 25 2002 1790 1794
12. N. Sattar, A. Gaw, and O. Scherbakova Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study Circulation 108 2003 414 419
13. H.M. Lakka, D.E. Laaksonen, and T.A. Lakka The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2002 2709 2716
14. C.J. Girman, T. Rhodes, and M. Mercuri 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Am J Cardiol 93 2004 136 141
15. R.W. Schrier, R.O. Estacio, A. Esler, and P. Mehler Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney Int 61 2002 1086 1097
16. P.H. Wang, J. Lau, and T.C. Chalmers Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes Lancet 341 1993 1306 1309
17. L.F. Fried, T.J. Orchard, and B.L. Kasiske Effect of lipid reduction on the progression of renal disease: a meta-analysis Kidney Int 59 2001 260 269
18. R.H. Eckel, S.M. Grundy, and P. Zimmet The metabolic syndrome Lancet 365 2005 1415 1428
19. S.S. Anand, Q. Yi, and H. Gerstein Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease Circulation 108 2003 420 425
20. D.W. Johnson, K. Armstrong, and S.B. Campbell Metabolic syndrome in severe chronic kidney disease: prevalence, predictors, prognostic significance and effects of risk factor modification Nephrology 12 2007 391 398
21. D. Simmons, and C.F. Thompson Prevalence of the metabolic syndrome among adult New Zealanders of Polynesian and European descent Diabetes Care 27 2004 3002 3004
22. V.G. Athyros, E.S. Ganotakis, and K. Tziomalos Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population Curr Med Res Opin 26 2010 713 719
23. M. Kurella, J.C. Lo, and G.M. Chertow Metabolic syndrome and the risk for chronic kidney disease among non-diabetic adults J Am Soc Nephrol 16 2005 2134 2140
24. S. Beddhu, P.L. Kimmel, N. Ramkumar, and A.K. Cheung Associations of metabolic syndrome with inflammation in CKD: results from the Third National Health and Nutrition Examination Survey (NHANES III) Am J Kidney Dis 46 2005 577 586
25. T. Shoji, and Y. Nishizawa Chronic kidney disease as a metabolic syndrome with malnutrition - need for strict control of risk factors Intern Med 44 2005 179 187
26. J. Chen, D. Gu, and C.-S. Chen Association between the metabolic syndrome and chronic kidney disease in Chinese adults Nephrol Dial Transplant 22 2007 1100 1106
27. C.M. Hoehner, K.J. Greenlund, S. Rith-Najarian, M.L. Casper, and W.M. McClellan Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project J Am Soc Nephrol 13 2002 1626 1634
28. J. Chen, P. Muntner, and L.L. Hamm The metabolic syndrome and chronic kidney disease in U.S. adults Ann Intern Med 140 2004 167 174
29. L. Palaniappan, M. Carnethon, and S.P. Fortmann Association between microalbuminuria and the metabolic syndrome: NHANES III Am J Hypertens 16 2003 952 958
30. M. Cignarelli, O. Lamacchia, and G. Cardinale Metabolic syndrome and albuminuria show an additive effect in modulating glomerular filtration rate in patients with type 2 diabetes mellitus Diabetes Metab Synd: Clin Res Rev 3 2009 139 142
31. A.O. Luk, W.Y. So, and R.C. Ma Hong Kong diabetes registry, metabolic syndrome predicts new onset of chronic kidney disease in 5829 patients with type 2 diabetes Diabetes Care 31 2008 2357 2361
32. V.G. Athyros, A. Karagiannis, and E.S. Ganotakis Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study Curr Med Res Opin 27 2011 1659 1668
33. H. Tanaka, Y. Shiohira, Y. Uezu, A. Higa, and K. Iseki Metabolic syndrome and chronic kidney disease in Okinawa, Japan Kidney Int 69 2006 369 374
34. D.O. Young, R.J. Lund, G. Haynatzki, and R.W. Dunlay Prevalence of the metabolic syndrome in an incident dialysis population Hemodial Int 11 2007 86 95
35. Y. Bao, X. Shang, L. Zhou, R. Hu, Y. Li, and W. Ding Relationship between N-terminal pro-B-type natriuretic peptide levels and metabolic syndrome Arch Med Sci 7 2011 247 256
36. M. Yu, D.R. Ryu, S.J. Kim, K.B. Choi, and D.H. Kang Clinical implication of metabolic syndrome on chronic kidney disease depends on gender and menopausal status: results from the Korean National Health and Nutrition Examination Survey Nephrol Dial Transplant 25 2010 469 477
37. E.S. Ford, W.H. Giles, and A.H. Mokdad Increasing prevalence of the metabolic syndrome among U.S. adults Diabetes Care 27 2004 2444 2449
38. S.R. Silbiger, and N. Neugarten The impact of gender on the progression of chronic renal disease Am J Kidney Dis 25 1995 515 533
39. X. Zhang, Y. Jia, E.K. Jackson, and S.P. Tofovic 2-Methoxyestradiol and 2-ethoxyestradiol retard the progression of renal disease in aged, obese, diabetic ZSF1 rats J Cardiovasc Pharmacol 49 2007 56 63
40. S. Domrongkitchaiporn, P. Sritara, and C. Kitiyakara Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study J Am Soc Nephrol 16 2005 791 799
41. L. Zhang, L. Zuo, and F. Wang Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older Mayo Clin Proc 82 2007 822 827
42. G. Mancia, M. Bombelli, and G. Corrao Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis Hypertension 49 2007 40 47
43. P. Deedwania Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers J Clin Hypertens (Greenwich) 13 2011 52 59
44. M. Banach, and J. Rysz Current problems in hypertension and nephrology Expert Opin Pharmacother 11 2010 2575 2578
45. T. Fujita Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome Hypertension 55 2010 813 818
46. A.P. Rocchini, J. Key, and D. Bondie The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents N Engl J Med 321 1989 580 585
47. T. Uzu, G. Kimura, and A. Yamauchi Enhanced sodium sensitivity and disturbed circadian rhythm of blood pressure in essential hypertension J Hypertens 24 2006 1627 1632
48. J. Chen, D. Gu, and J. Huang Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study Lancet 373 2009 829 835
49. J.E. Hall, H.L. Mizelle, D.A. Hildelbrandt, and M.W. Brands Abnormal pressure natriuresis: a cause or a consequence of hypertension? Hypertension 15 1990 547 559
50. J.E. Hall, J.J. Kuo, A.A. da Silva, R.B. de Paula, J. Liu, and L. Tallam Obesity-associated hypertension and kidney disease Curr Opin Nephrol Hypertens 12 2003 195 200
51. G. Grassi, M. Colombo, G. Seravalle, D. Spaziani, and G. Mancia Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure Hypertension 31 1998 64 67
52. G. Grassi, R. Dell'Oro, A. Facchini, F. Quarti Trevano, G.B. Bolla, and G. Mancia Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives J Hypertens 22 2004 2363 2369
53. K. Iseki Metabolic syndrome and chronic kidney disease: a Japanese perspective on a worldwide problem J Nephrol 21 2008 305 312
54. J.R. Sowers, and E.D. Fronlich Insulin and insulin resistance: impact on blood pressure and cardiovascular disease Med Clin North Am 88 2004 63 82
55. M. Ehrhart-Bornstein, V. Lamounier-Zepter, and A. Schraven Human adipocytes secrete mineralocorticoid-releasing factors Proc Natl Acad Sci U S A 100 2003 14211 14216
56. C.M. Boustany, K. Bharadwaj, A. Daugherty, D.R. Brown, D.C. Randall, and L.A. Cassis Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension Am J Physiol Regul Integr Comp Physiol 287 2004 R943 R949
57. P. Mundel, and S.J. Shankland Podocyte biology and response to injury J Am Soc Nephrol 13 2002 3005 3015
58. E.R. Blasi, R. Rocha, A.E. Rudolph, E.A. Blomme, M.L. Polly, and E.G. McMahon Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats Kidney Int 63 2003 1791 1800
59. L.H. Cavallari, L.A. Fashingbauer, J.R. Camp, S.T. King, and D.L. Geenen Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression J Renin Angiotensin Aldosterone Syst 9 2008 146 153
60. C. Vecchione, A. Maffei, and S. Colella Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway Diabetes 51 2002 168 173
61. H. Chen, M. Montagnani, T. Funahashi, I. Shimomura, and M.J. Quon Adiponectin stimulates production of nitric oxide in vascular endothelial cells J Biol Chem 278 2003 45021 45026
62. J. Ribstein, G. du Cailar, and A. Mimran Combined renal effects of overweight and hypertension Hypertension 26 1995 610 615
63. B.L. Kasiske, and J.T. Crosson Renal disease in patients with massive obesity Arch Intern Med 146 1986 1105 1109
64. D.J. Rea, J.K. Heimbach, and J.P. Grande Glomerular volume and renal histology in obese and non-obese living kidney donors Kidney Int 70 2006 1636 1641
65. C. Maric, and J.E. Hall Obesity, metabolic syndrome and diabetic nephropathy Contrib Nephrol 170 2011 28 35
66. B.E. Wisse The inflammatory syndrome. The role of adipose tissue cytokines in metabolic disorders linked to obesity J Am Soc Nephrol 15 2004 2792 2800
67. J.D. Kopple, and U. Feroze The effect of obesity on chronic kidney disease J Ren Nutr 21 2011 66 71
68. M. Tomaszewski, F.J. Charchar, and C. Maric Glomerular hyperfiltration: a new marker of metabolic risk Kidney Int 71 2007 816 821
69. A.T. Whaley-Connell, N.A. Chowdhury, and M.R. Hayden Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat Am J Physiol Renal Physiol 291 2006 F1308 F1314
70. J.R. Sowers Metabolic risk factors and renal disease Kidney Int 71 2007 719 720
71. J.E. Hall, M.W. Brands, and J.R. Henegar Mechanisms of hypertension and kidney disease in obesity Ann N Y Acad Sci 892 1999 91 107
72. A. Chagnac, T. Weinstein, A. Korzets, E. Ramadan, J. Hirsch, and U. Gafter Glomerular hemodynamics in severe obesity Am J Physiol Renal Physiol 278 2000 F817 F822
73. G. Ruotolo, and B.V. Howard Dyslipidemia of the metabolic syndrome Curr Cardiol Rep 4 2002 494 500
74. A. Gluba, J. Rysz, and M. Banach Statins in patients with chronic kidney disease: why, who and when? Expert Opin Pharmacother 11 2010 2665 2674
75. A. Cases, and E. Coll Dyslipidemia and the progression of renal disease in chronic renal failure patients Kidney Int 68 2005 S87 S93
76. J.A. Joles, U. Kunter, and U. Janssen Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats J Am Soc Nephrol 11 2000 669 683
77. P. Muntner, J. Coresh, J.C. Smith, J. Eckfeldt, and M.J. Klag Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study Kidney Int 58 2000 293 301
78. Y. Nishida, N. Yorioka, H. Oda, and M. Yamakido Effect of lipoproteins on cultured human mesangial cells Am J Kidney Dis 29 1997 919 930
79. S. Ryu, Y. Chang, and H.-Y. Woo Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes Am J Kidney Dis 53 2009 59 69
80. J.D. Bagdade, and J.J. Albers Plasma high-density lipoprotein concentrations in chronic-hemodialysis and renal-transplant patients N Engl J Med 296 1977 1436 1439
81. T. Miida, O. Miyazaki, and O. Hanyu LCAT-dependent conversion of pre β1-HDL into α-migrating HDL is severely delayed in hemodialysis patients J Am Soc Nephrol 14 2003 732 738
82. S. Seneff, G. Wainwright, and L. Mascitelli Is the metabolic syndrome caused by a high fructose, and relatively low fat, low cholesterol diet? Arch Med Sci 7 2011 8 20
83. B. Becker, F. Kronenberg, and J.T. Kielstein Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the Mild and Moderate Kidney Disease Study J Am Soc Nephrol 16 2005 1091 1098
84. K. Ohashi, H. Iwatani, and S. Kihara Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice Arterioscler Thromb Vasc Biol 27 2007 1910 1917
85. R.S. Ahima Linking adiponectin to proteinuria J Clin Invest 118 2008 1619 1622
86. R. Ouedraogo, Y. Gong, and B. Berzins Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo J Clin Invest 117 2007 1718 1726
87. J.W. Rowe, J.B. Young, K.L. Minaker, A.L. Stevens, J. Pallotta, and L. Landsberg Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man Diabetes 30 1981 219 225
88. R.A. DeFronzo, C.R. Cooke, R. Andres, G.R. Faloona, and P.J. Davis The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man J Clin Invest 55 1975 845 855
89. T. Clausen, and M.E. Everts Regulation of the Na, K-pump in skeletal muscle Kidney Int 35 1989 1 13
90. D.R. Dengel, A.P. Goldberg, R.S. Mayuga, G.M. Kairis, and M.R. Weir Insulin resistance, elevated glomerular filtration fraction, and renal injury Hypertension 28 1996 127 132
91. U. Ozcan, Q. Cao, and E. Yilmaz Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes Science 306 2004 457 461
92. D.J. Bridgewater, J. Ho, V. Sauro, and D.G. Matsell Insulin-like growth factors inhibit podocyte apoptosis through the PI3 kinase pathway Kidney Int 67 2005 1308 1314
93. R. Inagi Endoplasmic reticulum stress in the kidney as a novel mediator of kidney injury Nephron Exp Nephrol 112 2009 e1 e9
94. Y. Fujii, J. Khoshnoodi, and H. Takenaka The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases Kidney Int 69 2006 1350 1359
95. A.V. Cybulsky, T. Takano, J. Papillon, and K. Bijian Role of the endoplasmic reticulum unfolded protein response in glomerular epithelial cell injury J Biol Chem 280 2005 24396 24403
96. A.V. Cybulsky, T. Takano, J. Papillon, A. Khadir, J. Liu, and H. Peng Complement C5b-9 membrane attack complex increases expression of endoplasmic reticulum stress proteins in glomerular epithelial cells J Biol Chem 277 2002 41342 41351
97. M. Kitamura Endoplasmic reticulum stress and unfolded protein response in renal pathophysiology: Janus faces Am J Physiol Renal Physiol 295 2008 F323 F334
98. H. Zinszner, M. Kuroda, and X. Wang CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum Genes Dev 12 1998 982 995
99. T. Ohse, R. Inagi, and T. Tanaka Albumin induces endoplasmic reticulum stress and apoptosis in renal proximal tubular cells Kidney Int 70 2006 1447 1455
100. A. Kaser, A.H. Lee, and A. Franke XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease Cell 134 2008 743 756
101. C. Alan, H. Kocoglu, R. AltIntas, B. AlIcI, and A.R. Ersay Protective effect of decorin on acute ischaemia-reperfusion injury in the rat kidney Arch Med Sci 7 2011 211 216
102. K. Nagaraju, L. Casciola-Rosen, and I. Lundberg Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction Arthritis Rheum 52 2005 1824 1835
103. A. Rashidi, A. Ghanbarian, and F. Azizi Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population Clin J Am Soc Nephrol 2 2007 976 983
104. M.J. Klag, P.K. Whelton, and B.L. Randall Blood pressure and end-stage renal disease in men N Engl J Med 334 1996 13 18
105. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
106. M.J. Sarnak, A.S. Levey, and A.C. Schoolwerth Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 108 2003 2154 2169
107. A. Karagiannis, D. Mikhailidis, K. Tziomalos, A. Kakafika, and V. Athyros Has the time come for a new definition of microalbuminuria? Curr Vasc Pharmacol 6 2008 81 83
108. G. Efstratiadis, K. Tziomalos, D.P. Mikhailidis, V.G. Athyros, and A. Hatzitolios Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 6 2008 93 107
109. P.O. Attman, C. Knight-Gibson, M. Tavella, O. Samuelsson, and P. Alaupovic The compositional abnormalities of lipoproteins in diabetic renal failure Nephrol Dial Transplant 13 1998 2833 2841
110. D. Weiner, and M.J. Sarnak Managing dyslipidemia in chronic kidney disease J Gen Intern Med 19 2004 1045 1052
111. M. Kanbay, F. Turgut, A. Covic, and D. Goldsmith Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence J Nephrol 22 2009 598 609
112. P.O. Attman, O. Samuelsson, and P. Alaupovic Lipoprotein metabolism and renal failure Am J Kidney Dis 21 1993 573 592
113. Y. Zhao, and Y.L. Marcel Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins Biochemistry 35 1996 7174 7180
114. R.H. Mak Insulin and its role in chronic kidney disease Pediatr Nephrol 23 2008 355 362
115. R.H. Mak, C. Turner, T. Thompson, G.B. Haycock, and C. Chantler The effect of dietary protein restriction and amino acid/keto acid supplements on glucose metabolism in uremic children J Clin Endocrinol Metabol 63 1986 985 989
116. R.H. Mak 1,25 vitamin D3 corrects insulin and lipid abnormalities in uremia Kidney Int 53 1998 1353 1357
117. G.H. Mostbeck, R. Kain, and R. Mallek Duplex Doppler sonography in renal parenchymal disease. Histopathologic correlation J Ultrasound Med 10 1991 190 194
118. K.J. Mather, A. Lteif, H.O. Steinberg, and A.D. Baron Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes Diabetes 53 2004 2060 2066
119. S. Buscemi, S. Verga, and J.A. Batsis Intra-renal hemodynamics and carotid intima-media thickness in the metabolic syndrome Diabetes Res Clin Pract 86 2009 177 185
120. R.J. Johnson, J. Herrera-Acosta, G.F. Schreiner, and B. Rodriguez-Iturbe Subtle acquired renal injury as a mechanism of salt-sensitive hypertension N Engl J Med 346 2002 913 923
121. M.P. Alexander, T.V. Patel, Y.M.K. Farag, A. Florez, H.G. Rennke, and A.K. Singh Kidney pathological changes in metabolic syndrome: a cross-sectional study Am J Kidney Dis 53 2009 751 759
122. H. Scheuer, W. Gwinneeer, and J. Hohbach Oxidant stress in hyperlipidemia-induced renal damage Am J Physiol Renal Physiol 278 2000 F63 F74
123. J. Dominguez, P. Wu, C.S. Packer, C. Temm, and K.J. Kelly Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy Am J Physiol Renal Physiol 293 2007 F670 F679
124. D.K. Singh, P. Winocour, and K. Farrington Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy Nat Clin Pract Nephrol 4 2008 216 226
125. M. Ueno, S. Kawashima, and S. Nishi Tubulointerstitial lesions in non-insulin dependent diabetes mellitus Kidney Int Suppl 63 1997 S191 S
126. Z. Al-Aly Medial vascular calcification in diabetes mellitus and chronic kidney disease: the role of inflammation Cardiovasc Hematol Disord Drug Targets 7 2007 1 6
127. S. Kobayashi, H. Moriya, I. Nakabayashi, J. Nishiyama, and T. Fukuda Angiotensin II and IGF-I may interact to regulate tubulointerstitial cell kinetics and phenotypic changes in hypertensive rats Hypertens Res 25 2002 257 269
128. Z. Cao, and M.E. Cooper Role of angiotensin II in tubulointerstitial injury Semin Nephrol 21 2001 554 562
129. T. Nakagawa, D.H. Kang, and R. Ohashi Tubulointerstitial disease: role of ischemia and microvascular disease Curr Opin Nephrol Hypertens 12 2003 233 241
130. T. Kosugi, Y. Yuzawa, and W. Sato Midkine is involved in tubulointerstitial inflammation associated with diabetic nephropathy Lab Invest 87 2007 903 913
131. L.G. Sanchez-Lozada, E. Tapia, and A. Jimenez Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats Am J Physiol Renal Physiol 292 2007 F423 F429
132. T. Nakagawa, K.R. Tuttle, R.A. Short, and R.J. Johnson Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome Nat Clin Pract Nephrol 1 2005 80 86
133. A. Serra, R. Romero, and D. Lopez Renal injury in the extremely obese patients with normal renal function Kidney Int 73 2008 947 955
134. B. West, A. Luke, R.A. Durazo-Arvizu, G. Cao, D. Shoham, and H. Kramer Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994 Am J Kidney Dis 51 2008 741 747
135. D. Rendina, G. Mossetti, and G. De Filippo Association between metabolic syndrome and nephrolithiasis in an inpatient population in southern Italy: role of gender, hypertension and abdominal obesity Nephrol Dial Transplant 24 2009 900 906
136. P. Cochat, V. Pichault, and J. Bacchetta Nephrolithiasis related to inborn metabolic diseases Pediatr Nephrol 25 2010 415 424
137. K. Sakhaee Recent advances in the pathophysiology of nephrolithiasis Kidney Int 75 2009 585 595
138. N. Abate, M. Chandalia, A.V. Cabo-Chan, O.W. Moe, and K. Sakhaee The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance Kidney Int 65 2004 386 392
139. E.N. Taylor, M.J. Stampfer, and G.C. Curhan Obesity, weight gain, and the risk of kidney stones JAMA 293 2005 455 462
140. A. Cupisti, M. Meola, and C. D'Alessandro Insulin resistance and low urinary citrate excretion in calcium stone formers Biomed Pharmacother 61 2007 86 90
141. J. Klisic, M.C. Hu, and V. Nief Insulin activates Na(+)/H(+) exchanger 3: biphasic response and glucocorticoid dependence Am J Physiol Renal Physiol 283 2002 F532 F539
142. M.C. Chobanian, and M.R. Hammerman Insulin stimulates ammoniagenesis in canine renal proximal tubular segments Am J Physiol 253 1987 F1171 F1177
143. K. Sakhaee, and N.M. Maalouf Metabolic syndrome and uric acid nephrolithiasis Semin Nephrol 28 2008 174 180
144. F. Madore, M.J. Stampfer, and E.B. Rimm Nephrolithiasis and risk of hypertension Am J Hypertens 11 1998 46 53
145. F.P. Cappuccio, A. Siani, and G. Barba A prospective study of hypertension and the incidence of kidney stones in men J Hypertens 17 1999 1017 1022
146. P. Strazzullo, F. Galletti, and M. Cirillo Altered extracellular calcium homoeostasis in essential hypertension: a consequence of abnormal cell calcium handling Clin Sci (Lond) 71 1986 239 244
147. S.H. Obligado, and D.S. Goldfarb The association of nephrolithiasis with hypertension and obesity: a review Am J Hypertens 21 2008 257 264
148. K. Kalantar-Zadeh, G. Block, M.H. Humphreys, and J.D. Kopple Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients Kidney Int 63 2003 793 808
149. M. Navarro-Diaz, A. Serra, and R. Romero Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up J Am Soc Nephrol 17 2006 S213 S217
150. S. Kini, D.M. Herron, and R.T. Yanagisawa Bariatric surgery for morbid obesity: a cure for metabolic syndrome Med Clin North Am 91 2007 2125 2171
151. S. Hallan, R. de Mutsert, S. Carlsen, F.W. Dekker, K. Aasarod, and J. Holmen Obesity, smoking and physical inactivity as risk factors for CKD: are men more vulnerable? Am J Kidney Dis 47 2006 396 405
152. National Institutes of Health Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report Obes Res 2 Suppl. 6 1998 51S 209S (Erratum in: Obes Res 1998; 6:464)
153. J. Redon, R. Cifkova, and S. Laurent The metabolic syndrome in hypertension: European society of hypertension position statement J Hypertens 26 2008 1891 1900
154. H. Yki-Järvinen Thiazolidinediones N. J. Engl Med 351 2004 1106 1118
155. J.P. Despres, A. Golay, L. Sjostrom Rimonabant in Obesity-Lipids Study Group Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia N Engl J Med 353 2005 2121 2134
156. F.X. Pi-Sunyer, L.J. Aronne, H.M. Heshmati, J. Devin, J. Rosenstock RIO-North America Study Group Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial JAMA 295 2006 761 775
157. L.M. Ruilope, J.P. Despres, and A. Scheen Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results J Hypertens 26 2008 357 367
158. A. Zanchetti, M. Hennig, and H. Baurecht Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness J Hypertens 25 2007 2463 2470
159. J. Rysz, M. Banach, and R.A. Stolarek Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy J Nephrol 20 2007 444 452
160. J.A. Garcia-Donaire, J. Segura, and L.M. Ruilope Clinical trials in nephrology: success or failure Curr Opin Nephrol Hypertens 16 2007 59 63
161. P. Korantzopoulos, M. Elisaf, and H.J. Milionis Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney disease - ready for prime time? Nephrol Dial Transplant 22 2007 2768 2774
162. M. Banach, D.P. Mikhailidis, S.E. Kjeldsen, and J. Rysz Time for new indications for statins? Med Sci Monit 15 12 2009 MS1 MS5
163. H.J. Milionis, E.N. Liberopoulos, A. Achimastos, M.S. Elisaf, and D.P. Mikhailidis Statins: another class of antihypertensive agents? J Hum Hypertens 20 2006 320 335
164. P. Strazzullo, S.M. Kerry, A. Barbato, M. Versiero, L. D'Elia, and F.P. Cappuccio Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials Hypertension 49 2007 792 798
165. M. Stepien, M. Banach, D.P. Mikhailidis, A. Gluba, S.E. Kjeldsen, and J. Rysz Role and significance of statins in the treatment of hypertensive patients Curr Med Res Opin 25 2009 1995 2005
166. W.F. Keane, B.L. Kasiske, and M.P. O'Donnell The role of altered lipid metabolism in the progression of renal disease: experimental evidence Am J Kidney Dis 17 Suppl. 1 1991 38 42
167. S. Vázquez-Pérez, P. Aragoncillo, and N. de Las Heras Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits Nephrol Dial Transplant 16 Suppl. 1 2001 40 44
168. U. Aydin, M. Ugurlucan, and F. Gungor Effects of atorvastatin on vascular intimal hyperplasia: an experimental rodent model Angiology 60 2009 370 377
169. G.F. Strippoli, S.D. Navaneethan, and D.W. Johnson Effects of statins in patients with chronic kidney disease: metaanalysis and meta-regression of randomised controlled trials BMJ 336 2008 645 651
170. J. Rysz, W.S. Aronow, R.S. Stolarek, S. Hannam, D.P. Mikhailidis, and M. Banach Nephroprotective and clinical potential of statins in dialyzed patients Expert Opin Ther Targets 13 2009 541 550
171. S. Bianchi, R. Bigazzi, and A. Caiazza A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Am J Kidney Dis 41 2003 565 570
172. A. Verma, K.M. Ranganna, R.S. Reddy, M. Verma, and N.F. Gordon Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease Am J Cardiol 96 2005 1290 1292
173. M. Colhoun, J. Betteridge, and P.N. Durrington Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) Am J Kidney Dis 54 2009 810 819
174. V.G. Athyros, A.I. Kakafika, and A.A. Papageorgiou Statin-induced increase in HDL-C and renal function in coronary heart disease patients Open Cardiovasc Med J 1 2007 8 14
175. S. Sandhu, N. Wiebe, L.F. Fried, and M. Tonelli Statins for improving renal outcomes: a meta-analysis J Am Soc Nephrol 17 2006 2006 2016
176. M. Tonelli, L. Moye, F.M. Sacks, T. Cole, G.C. Curhan Cholesterol and Recurrent Events (CARE) Trial Investigators Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease J Am Soc Nephrol 14 2003 1605 1613
177. I. Szadkowska, A. Stanczyk, and W.S. Aronow Statin therapy in the elderly: a review Arch Gerontol Geriatr 50 2010 114 118
178. K. Douglas, P.G. O'Malley, and J.L. Jackson Meta-analysis: the effect of statins on albuminuria Ann Intern Med 145 2006 117 124
179. J. Shepherd, J.J.P. Kastelein, and V.A. Bittner Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease Mayo Clin Proc 83 2008 870 879
180. M. Rahman, C. Baimbridge, and B.R. Davis Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Am J Kidney Dis 52 2008 412 424
181. S. Bianchi, D. Grimaldi, and R. Bigazzi Statins and lipid-lowering strategies in cardiorenal patients Contrib Nephrol 171 2011 143 150
182. B. Staels, and J.C. Fruchart Therapeutic roles of peroxisome proliferator-activated receptor agonists Diabetes 54 2005 2460 2470
183. Z. Varghese, J.F. Moorhead, and X.Z. Ruan The PPAR-alpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy Kidney Int 69 2006 1490 1491
184. A. Keech, R.J. Simes, and P. Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
185. J.C. Ansquer, C. Foucher, S. Rattier, M.R. Taskinen, and G. Steiner DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am J Kidney Dis 45 2005 485 493
186. M.J. Caslake, C.J. Packard, and A. Gaw Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia Arterioscler Thromb 13 1993 702 711
187. V. Tsimihodimos, A. Kakafika, and M. Elisaf Fibrate treatment increase serum creatinine levels Nephrol Dial Transplant 16 2001 1301
188. P.J. Barter, and K.-A. Rye Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 28 2008 39 46
189. M. Barylski, M. Banach, D.P. Mikhailidis, L. Pawlicki, and J. Kowalski Decreased kidney function as a risk factor for cardiovascular events in subjects with metabolic syndrome - a pilot study Arch Med Sci 4 2008 417 423
190. M.S. Kostapanos, G.L. Liamis, and M. Elisaf Features of the metabolic syndrome relating to cardiorenal outcomes Arch Med Sci 4 2008 424 426
191. M. Barylski, E. Kowalczyk, M. Banach, J. Ciecwierz, L. Pawlicki, and J. Kowalski Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome Angiology 60 2009 87 92